FASA Sec. 1555 repeal exemption for AIDS drugs under consideration; additional ADAP funding sought.
FASA SEC. 1555 REPEAL CONTESTED BY REP. WAXMAN (D-CALIF.) in May 16 letters to Reps. Obey (D-Wisc.) and Hoyer (D-Md.), the ranking Democrats on the House Appropriations Committee and the Appropriations/Treasury Subcommittee, respectively. Language included in the Senate version of the emergency supplemental appropriations bill (S 637) would repeal the federal cooperative purchasing program established by Sec. 1555 of the Federal Acquisitions Streamlining Act. The House version of the appropriations bill (HR 1469) passed May 15 does not include language addressing the FASA measure; legislators plan to resolve the issue in conference during the week of May 19.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth